Rebecca Dent, MD
Adding the AKT inhibitor ipatasertib to paclitaxel improved median overall survival (OS) by 5 months for patients with locally advanced or metastatic triple-negative breast cancer (TNBC), according to results presented at the 2018 ASCO Annual Meeting.
In interim survival data from the intent-to-treat (ITT) population of the randomized, placebo-controlled phase II LOTUS trial (NCT02162719), ipatasertib improved median OS to 23.1 months compared with 18.4 months with paclitaxel and placebo (stratified HR, 0.62; 95% CI, 0.37-1.05). The 1-year OS rate increased from 70% to 83% with the addition of ipatasertib.
... to read the full story